Xyzagen Expands Laboratory in Pittsboro and Expands Services into In Vitro ADME Assays
Pittsboro, NC – October 1, 2023 – Xyzagen, Inc., a leading pharmacokinetics consultancy and contract research organization (CRO), announced today the expansion of its laboratory in Pittsboro, North Carolina. This expansion also marked the introduction of in vitro ADME (Absorption, Distribution, Metabolism, and Excretion) assays, discovery drug substance and drug product stability assesssments and RT-PCR capabilities, significantly broadening the company’s service offerings.
“We are excited to expand our capabilities to support early phase drug discovery and development organizations,” said Christopher Crean, CEO and Founder at Xyzagen. “This expansion represents a key milestone in our ongoing commitment to providing cost effective research solutions for our clients in the pharmaceutical industry.”
About Xyzagen, Inc.
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late stage clinical noncompartmental PK, PopPK and Quantitative Medicine. Our knowledge in pharmacology and pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. Xyzagen’s a boutique organization which allows small clients to work directly and strategically with experts during their drug development programs.
Media Contact:
Christopher Crean
Founder & CEO, Xyzagen, Inc.
Phone: (919) 762-2072
Email: [email protected]
